Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares, rose in value on Thursday, March 06, with the stock price down by -0.79% to the previous day’s close as strong demand from buyers drove the stock to $2.51.
Actively observing the price movement in the last trading, the stock closed the session at $2.53. Referring to stock’s 52-week performance, its high was $5.02, and the low was $2.25. On the whole, MREO has fluctuated by -20.57% over the past month.
With the market capitalization of Mereo Biopharma Group Plc ADR currently standing at about $388.37 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
The stock’s technical analysis shows that the price of MREO currently trading nearly -8.16% and -17.89% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.92, while the 7-day volatility ratio is showing 7.27% which for the 30-day chart, stands at 5.78%. Furthermore, Mereo Biopharma Group Plc ADR (MREO)’s beta value is 0.61, and its average true range (ATR) is 0.17.
A comparison of Mereo Biopharma Group Plc ADR (MREO) with its peers suggests the former has fared considerably weaker in the market. MREO showed an intraday change of -0.79% in last session, and over the past year, it shrunk by -34.97%%.
Data on historical trading for Mereo Biopharma Group Plc ADR (NASDAQ:MREO) indicates that the trading volumes over the past 3 months, they’ve averaged 1.21 million. According to company’s latest data on outstanding shares, there are 154.73 million shares outstanding.
Nearly 8.04% of Mereo Biopharma Group Plc ADR’s shares belong to company insiders and institutional investors own 66.46% of the company’s shares. The stock has fallen by -28.29% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MREO stock heading into the next quarter.
